Samuel Lee's questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q2 2025
Question
Samuel Lee, on for Greg Svanihan, inquired about potential patient compliance issues with a daily injectable like Avexatide and asked for feedback from the physician community following the recent ENDO conference.
Answer
Co-CEO & Co-Founder Josh Cohen noted that past trials showed near-100% compliance and market research indicates patients are not concerned, viewing it favorably compared to frequent finger sticks. Chief Medical Officer Dr. Camille Bedrosian added that physician feedback from ENDO was very positive, with growing awareness and excitement about a potential treatment.